Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABEO Stock Forecast 2026-2027
$5.67
Current Price
$323.16M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ABEO Price Targets
+393.8%
To High Target of $28.00
+252.7%
To Median Target of $20.00
+146.9%
To Low Target of $14.00
ABEO Price Momentum
+4.0%
1 Week Change
+3.3%
1 Month Change
-5.0%
1 Year Change
+7.6%
Year-to-Date Change
-24.8%
From 52W High of $7.54
+41.8%
From 52W Low of $4.00
📊 TOP ANALYST CALLS
Did ABEO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Abeona is one of their latest high-conviction picks.
Latest ABEO Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ABEO has a bullish consensus with a median price target of $20.00 (ranging from $14.00 to $28.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $5.67, the median forecast implies a 252.7% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Liav Abraham at Citigroup, projecting a 393.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABEO Analyst Ratings
6
Buy
0
Hold
0
Sell
ABEO Price Target Range
Low
$14.00
Average
$20.00
High
$28.00
Current: $5.67
Latest ABEO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABEO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Mar 19, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 10, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 18, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 15, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Jul 16, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 14, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 2, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Assumes | $19.00 |
| May 16, 2025 | Stifel | Buy | Maintains | $N/A | |
| Apr 30, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 24, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 5, 2025 | Oppenheimer | Outperform | Initiates | $N/A | |
| Feb 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 25, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 31, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 29, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Sep 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $18.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Abeona Therapeutics Inc. (ABEO) Competitors
The following stocks are similar to Abeona based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Abeona Therapeutics Inc. (ABEO) Financial Data
Abeona Therapeutics Inc. has a market capitalization of $323.16M with a P/E ratio of 5.8x. The company generates $14.54M in trailing twelve-month revenue with a 454.9% profit margin.
Revenue growth is +60.9% quarter-over-quarter, while maintaining an operating margin of -264.1% and return on equity of +71.0%.
Valuation Metrics
Market Cap
$323.16M
Enterprise Value
$170.09M
P/E Ratio
5.8x
PEG Ratio
0.2x
Price/Sales
21.7x
Growth & Margins
Revenue Growth (YoY)
+60.9%
Gross Margin
+69.1%
Operating Margin
-264.1%
Net Margin
+454.9%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+52.1%
Current Ratio
5.9x
Debt/Equity
16.0x
ROE
+71.0%
ROA
-38.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Abeona Therapeutics Inc. (ABEO) Business Model
About Abeona Therapeutics Inc.
What They Do
Develops cell and gene therapies for rare diseases.
Business Model
Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company focusing on cell and gene therapies. The company generates revenue through the development of its therapeutic candidates, which aim to address serious genetic disorders and rare diseases. Its advanced platforms, including AAV gene therapies, are designed to provide durable treatment effects from single administrations, potentially transforming patient outcomes in high-unmet-need areas.
Additional Information
Founded in 1974 and headquartered in Cleveland, Ohio, Abeona Therapeutics is engaged in extensive research and clinical development. The company collaborates with academic institutions, clinical investigators, and industry partners to enhance its pipeline and facilitate the adoption of innovative gene-based treatments in the pharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
136
CEO
Dr. Vishwas Seshadri M.B.A., Ph.D.
Country
United States
IPO Year
1980
Website
www.abeonatherapeutics.comAbeona Therapeutics Inc. (ABEO) Latest News & Analysis
Latest News
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 days ago
Quick Summary
Abeona Therapeutics Inc. granted equity awards to new non-executive employees, complying with Nasdaq Listing Rule 5635(c)(4).
Why It Matters
Abeona's equity awards to new employees can indicate growth and confidence in future performance, potentially boosting stock value and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Abeona Therapeutics Inc. (Nasdaq: ABEO) will have its management team participate in investor conferences in June 2026, as announced on May 26, 2026.
Why It Matters
Abeona Therapeutics' participation in investor conferences can signal potential developments or updates, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Abeona Therapeutics Inc. (NASDAQ:ABEO) released its first-quarter earnings report on Wednesday prior to market opening.
Why It Matters
Abeona Therapeutics' earnings report can influence stock performance and investor sentiment, impacting share price and future market expectations.
Source: Benzinga
Market Sentiment:
Positive
Abeona Therapeutics Q1 Earnings Call Highlights
1 month ago
Quick Summary
Abeona Therapeutics (NASDAQ: ABEO) reported early commercial success for ZEVASKYN in Q1 2026, noting new patient treatments and expanded treatment-center activation, plus a licensed prostate cancer therapy.
Why It Matters
Abeona Therapeutics' early commercial success with ZEVASKYN and new treatment initiatives indicate growth potential, which may positively impact stock performance and investor sentiment.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Abeona Therapeutics Inc. (ABEO) held its Q1 2026 earnings call, discussing financial performance and updates on ongoing projects and initiatives.
Why It Matters
Abeona Therapeutics' earnings call provides insights into financial performance, growth prospects, and strategic direction, crucial for assessing investment potential and future stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Abeona Therapeutics reported Q1 2026 results, noting three patients treated with ZEVASKYN and an expanding QTC network. The company has $168.3M in cash and is prioritizing T-cell technology over ophthalmology.
Why It Matters
Abeona Therapeutics shows growing adoption of ZEVASKYN, expanding treatment sites and financial stability with $168.3M in cash. This signals potential for revenue growth and innovation in cancer treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ABEO Stock
What is Abeona Therapeutics Inc.'s (ABEO) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Abeona Therapeutics Inc. (ABEO) has a median price target of $20.00. The highest price target is $28.00 and the lowest is $14.00.
Is ABEO stock a good investment in 2026?
According to current analyst ratings, ABEO has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABEO stock?
Wall Street analysts predict ABEO stock could reach $20.00 in the next 12 months. This represents a 252.7% increase from the current price of $5.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Abeona Therapeutics Inc.'s business model?
Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company focusing on cell and gene therapies. The company generates revenue through the development of its therapeutic candidates, which aim to address serious genetic disorders and rare diseases. Its advanced platforms, including AAV gene therapies, are designed to provide durable treatment effects from single administrations, potentially transforming patient outcomes in high-unmet-need areas.
What is the highest forecasted price for ABEO Abeona Therapeutics Inc.?
The highest price target for ABEO is $28.00 from Liav Abraham at Citigroup, which represents a 393.8% increase from the current price of $5.67.
What is the lowest forecasted price for ABEO Abeona Therapeutics Inc.?
Price targets from Wall Street analysts for ABEO are not currently available. The stock is trading at $5.67.
What is the overall ABEO consensus from analysts for Abeona Therapeutics Inc.?
The overall analyst consensus for ABEO is bullish. Out of 8 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are ABEO stock price projections?
Stock price projections, including those for Abeona Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 9:39 AM UTC